供货705万给院长回扣247万，整治医药商业贿赂须“行贿受贿一起查”

Core Viewpoint - The article highlights the rampant issue of commercial bribery in the medical sector, particularly focusing on the recent cases exposed by the National Medical Insurance Administration, which reflect a systemic problem that undermines fair competition and increases medical costs for patients and insurance funds [2][3]. Group 1: Recent Cases of Bribery - The article discusses a case involving a hospital director in Shaanxi who illegally accepted bribes totaling 2.72 million yuan, primarily from orthopedic consumables, with suppliers paying a 35% kickback on total supply amounts [2]. - This case is part of a broader trend, with the National Medical Insurance Administration previously exposing similar bribery cases in Heilongjiang, Chongqing, and Yunnan, indicating a widespread issue in the medical industry [2]. Group 2: Nature of Commercial Bribery - Commercial bribery in the medical field distorts prescription rights and disrupts normal medical practices, leading to increased medical burdens and a shift from competition based on clinical value to competition driven by high kickbacks [3]. - The article emphasizes that the high kickback rates, such as the 35% observed in the Shaanxi case, suggest significant price inflation in medical products, which ultimately contributes to the rising costs of healthcare for patients [4]. Group 3: Systemic Issues and Reforms - The article points out that the persistence of commercial bribery is linked to complex interest chains and institutional loopholes, particularly in high-value consumables and pharmaceuticals, where "kickback sales" have become a common practice [3]. - It advocates for comprehensive reforms in the medical procurement system, including expanding volume-based procurement to reduce unreasonable profit margins and combat bribery [5]. Group 4: Recommendations for Combating Bribery - The article suggests a multi-faceted approach to eradicate commercial bribery, including strict enforcement of laws against both bribery and receiving bribes, improving internal decision-making and supervision mechanisms in medical institutions, and enhancing monitoring of medical insurance funds [5][6]. - It highlights the necessity of treating bribery and receiving bribes as interconnected issues, with legal frameworks supporting joint investigations and penalties for both parties involved [6]. Group 5: Broader Implications - The article concludes that corruption in the medical field not only affects public finances but also jeopardizes public health and social equity, emphasizing the need for ongoing regulatory efforts to cleanse the industry and protect the well-being of citizens [7].